Cantor Fitzgerald set a $20.00 price target on Neos Therapeutics (NASDAQ:NEOS) in a research note released on Friday. The brokerage currently has a buy rating on the stock. Cantor Fitzgerald also issued estimates for Neos Therapeutics’ FY2018 earnings at ($1.86) EPS.
“Neos held its Analyst Day on March 22-23, which included a dinner with management and Behavioral Medicine KOLs Dr. Brian Barash and Dr. Birgit Amann, a presentation, and a manufacturing facility tour.”,” Cantor Fitzgerald’s analyst commented.
NEOS has been the topic of a number of other research reports. Zacks Investment Research lowered Neos Therapeutics from a hold rating to a sell rating in a research report on Thursday, January 25th. BidaskClub raised Neos Therapeutics from a sell rating to a hold rating in a research report on Wednesday, December 27th. BMO Capital Markets lowered Neos Therapeutics from an outperform rating to a market perform rating in a research report on Wednesday, January 31st. Finally, Wells Fargo set a $14.00 price target on Neos Therapeutics and gave the stock a buy rating in a research report on Saturday, March 17th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The company has an average rating of Hold and an average price target of $15.00.
Neos Therapeutics (NASDAQ NEOS) remained flat at $$8.85 during midday trading on Friday. The stock had a trading volume of 326,168 shares, compared to its average volume of 321,430. The company has a market cap of $256.62, a price-to-earnings ratio of -3.19 and a beta of -0.20. The company has a debt-to-equity ratio of 7.47, a current ratio of 2.20 and a quick ratio of 2.14. Neos Therapeutics has a fifty-two week low of $6.30 and a fifty-two week high of $13.15.
Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings results on Thursday, March 15th. The company reported ($0.49) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.61) by $0.12. The company had revenue of $7.79 million for the quarter, compared to analyst estimates of $9.30 million. Neos Therapeutics had a negative return on equity of 437.92% and a negative net margin of 264.80%. sell-side analysts expect that Neos Therapeutics will post -1.53 EPS for the current fiscal year.
Large investors have recently bought and sold shares of the stock. Essex Investment Management Co. LLC grew its holdings in shares of Neos Therapeutics by 3.5% during the fourth quarter. Essex Investment Management Co. LLC now owns 246,523 shares of the company’s stock worth $2,515,000 after buying an additional 8,371 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Neos Therapeutics by 20.9% during the second quarter. Northern Trust Corp now owns 201,266 shares of the company’s stock worth $1,470,000 after buying an additional 34,767 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of Neos Therapeutics during the third quarter worth about $617,000. Lyon Street Capital LLC bought a new position in shares of Neos Therapeutics during the third quarter worth about $2,063,000. Finally, Vanguard Group Inc. grew its holdings in shares of Neos Therapeutics by 25.7% during the second quarter. Vanguard Group Inc. now owns 740,160 shares of the company’s stock worth $5,403,000 after buying an additional 151,166 shares in the last quarter. Institutional investors and hedge funds own 49.33% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Neos Therapeutics (NEOS) Given a $20.00 Price Target at Cantor Fitzgerald” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/03/24/neos-therapeutics-neos-given-a-20-00-price-target-at-cantor-fitzgerald.html.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.